Microbot Medical INC 8-K filings

Microbot Medical announces its collaboration with Corewell Health demonstrates the feasibility of using the LIBERTY Endovascular Robotic System for remote coronary procedures.

Microbot Medical successfully closes a $13 million registered direct offering and concurrent private placement to fund the development and commercialization of its LIBERTY Robotic System.

Microbot Medical Inc. has entered into definitive agreements for a $13 million registered direct offering priced at-the-market under Nasdaq rules, along with a concurrent private placement of preferred investment options.

Microbot Medical announces the closing of registered direct offerings and concurrent private placements, raising $15.6 million, and anticipates FDA clearance for its LIBERTY Endovascular Robotic System in Q2 2025.

Microbot Medical increases the base salaries and potential bonus for key executives, effective for the 2025 fiscal year.

Microbot Medical's ACCESS-PVI trial data on the LIBERTY Endovascular Robotic System will be presented at the Society of Interventional Radiology (SIR) annual meeting.

Microbot Medical Inc. announces it has regained compliance with Nasdaq's minimum bid price rule after its common stock price remained above $1.00 for 15 consecutive business days.

Microbot Medical Inc. approved a special bonus of approximately $150,000 for its CEO, President, and Chairman, Harel Gadot, on January 17, 2025.

Microbot Medical has appointed Michal Ahuvia as Director of Operations to enhance production efficiencies in preparation for the commercial launch of their LIBERTY robotic system in the second quarter of 2025.

Microbot Medical has announced an $8.6 million registered direct offering priced at-the-market, along with a concurrent private placement of preferred investment options.

Microbot Medical has announced a $7 million capital raise through a registered direct offering and a concurrent private placement of preferred investment options.

Microbot Medical has completed its at-the-market offering, raising approximately $4.8 million through the sale of over 4.2 million shares.

Microbot Medical concludes 2024 by achieving key milestones, including the FDA 510(k) submission for its LIBERTY Endovascular Robotic System, and shifts focus to commercial launch preparations in 2025.

Microbot Medical has appointed David J. Wilson as a Class III director and member of the Audit and Compensation Committees, while also increasing the number of authorized shares for its 2020 Omnibus Performance Award Plan.

Microbot Medical has submitted a 510(k) premarket notification to the FDA for its LIBERTY Endovascular Robotic System, following successful clinical trials.

Microbot Medical Inc. has released updated presentation materials, which are expected to be available on their website on or about October 31, 2024.

Microbot Medical has successfully completed patient enrollment for its ACCESS-PVI clinical trial and is accelerating its go-to-market strategy for the LIBERTY robotic surgical system.

Microbot Medical Inc. received a notice from Nasdaq for failing to maintain a minimum share price of $1.00, placing the company at risk of delisting.

Microbot Medical reports accelerated patient enrollment in its ACCESS-PVI trial, expecting earlier completion and remains on track for a 510(k) FDA submission by the end of 2024.

Microbot Medical has successfully completed enrollment and follow-up for 50% of patients in its pivotal clinical trial for the LIBERTY Endovascular Robotic Surgical System.

Microbot Medical Inc. has released updated presentation materials, which will be available on their website.

Microbot Medical has announced a Phase 2 collaboration with Corewell Health to further develop remote telesurgery capabilities using the LIBERTY Endovascular Robotic System.

Microbot Medical has received ISO 13485:2016 certification for its quality management system, a key step towards obtaining regulatory approvals in Europe and streamlining compliance with revised FDA regulations.

Microbot Medical has partnered with Emory University to explore the integration of its LIBERTY robotic system with imaging technology for autonomous endovascular procedures.

Microbot Medical has finalized the enrollment of clinical sites for its pivotal human trial of the LIBERTY Endovascular Robotic Surgical System with the addition of Memorial Sloan Kettering Cancer Center.

Microbot Medical announces the second clinical site, Baptist Hospital of Miami, has successfully completed its first procedure using the LIBERTY Endovascular Robotic Surgical System as part of its pivotal human clinical trial.

Microbot Medical successfully completed the first human procedure using its LIBERTY Endovascular Robotic Surgical System as part of its pivotal clinical trial.

Microbot Medical has secured a second clinical trial site at Baptist Hospital of Miami for its LIBERTY Endovascular Robotic Surgical System.

Microbot Medical Inc. has amended its at-the-market offering agreement to facilitate the sale of up to $4.8 million in common stock under a new registration statement.

Microbot Medical has announced that Brigham and Women's Hospital will participate as a clinical trial site for its LIBERTY Endovascular Robotic Surgical System.